Free Trial
→ SpaceX IPO hides a much bigger story (From Weiss Ratings) (Ad)tc pixel Free DSGN Stock Alerts

Design Therapeutics (DSGN) Financials

Design Therapeutics logo
$13.15 -0.26 (-1.94%)
As of 11:27 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Design Therapeutics

Annual Income Statements for Design Therapeutics

This table shows Design Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -8.28 -36 -63 -67 -50 -70
Consolidated Net Income / (Loss)		 -8.28 -36 -63 -67 -50 -70
Net Income / (Loss) Continuing Operations		 -8.28 -36 -63 -67 -50 -70
Total Pre-Tax Income 		-8.28 -36 -63 -67 -50 -70
Total Operating Income		 -8.33 -36 -68 -78 -62 -79
Total Gross Profit		 0.23 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.23 0.00 0.00 0.00 0.00 0.00
Operating Revenue		 0.23 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 8.56 36 68 78 62 79
Selling, General & Admin Expense		 2.50 11 19 21 18 20
Research & Development Expense		 6.06 25 49 57 44 59
Total Other Income / (Expense), net		 0.05 0.30 4.29 11 13 9.68
Interest & Investment Income		 - - - 11 13 9.68
Basic Earnings per Share		 ($0.52) ($0.77) ($1.14) ($1.19) ($0.88) ($1.22)
Weighted Average Basic Shares Outstanding		 15.80M 45.94M 55.71M 55.98M 56.59M 57.33M
Diluted Earnings per Share		 ($0.52) ($0.77) ($1.14) ($1.19) ($0.88) ($1.22)
Weighted Average Diluted Shares Outstanding		 15.80M 45.94M 55.71M 55.98M 56.59M 57.33M
Weighted Average Basic & Diluted Shares Outstanding		 15.80M 45.94M 55.94M 56.49M 56.76M 61.67M

Quarterly Income Statements for Design Therapeutics

This table shows Design Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -16 -12 -11 -12 -13 -14 -18 -19 -17 -16 -18
Consolidated Net Income / (Loss)		 -16 -12 -11 -12 -13 -14 -18 -19 -17 -16 -18
Net Income / (Loss) Continuing Operations		 -16 -12 -11 -12 -13 -14 -18 -19 -17 -16 -18
Total Pre-Tax Income 		-16 -12 -11 -12 -13 -14 -18 -19 -17 -16 -18
Total Operating Income		 -19 -15 -14 -15 -16 -17 -20 -22 -19 -18 -20
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 19 15 14 15 16 17 20 22 19 18 20
Selling, General & Admin Expense		 5.57 4.11 4.60 4.53 4.37 4.54 5.04 5.83 4.72 4.74 5.33
Research & Development Expense		 13 11 9.80 11 12 12 15 16 15 13 14
Total Other Income / (Expense), net		 3.03 3.28 3.30 3.25 3.21 3.04 2.70 2.49 2.31 2.17 2.07
Interest & Investment Income		 - - 3.30 3.25 3.21 - 2.70 2.49 2.31 2.17 2.07
Other Income / (Expense), net		 3.03 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Basic Earnings per Share		 ($0.28) ($0.20) ($0.20) ($0.21) ($0.23) ($0.24) ($0.31) ($0.34) ($0.30) ($0.27) ($0.29)
Weighted Average Basic Shares Outstanding		 55.99M 55.98M 56.49M 56.56M 56.62M 56.59M 56.76M 56.86M 56.95M 57.33M 61.43M
Diluted Earnings per Share		 ($0.28) ($0.20) ($0.20) ($0.21) ($0.23) ($0.24) ($0.31) ($0.34) ($0.30) ($0.27) ($0.29)
Weighted Average Diluted Shares Outstanding		 55.99M 55.98M 56.49M 56.56M 56.62M 56.59M 56.76M 56.86M 56.95M 57.33M 61.43M
Weighted Average Basic & Diluted Shares Outstanding		 56.00M 56.49M 56.50M 56.62M 56.62M 56.76M 56.77M 56.95M 56.96M 61.67M 62.46M

Annual Cash Flow Statements for Design Therapeutics

This table details how cash moves in and out of Design Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 2.30 296 -272 -5.30 1.36 -5.71
Net Cash From Operating Activities		 -8.67 -29 -51 -59 -43 -54
Net Cash From Continuing Operating Activities		 -8.67 -29 -51 -59 -43 -54
Net Income / (Loss) Continuing Operations		 -8.28 -36 -63 -67 -50 -70
Consolidated Net Income / (Loss)		 -8.28 -36 -63 -67 -50 -70
Depreciation Expense		 0.01 0.13 0.41 0.54 0.60 0.62
Amortization Expense		 -0.07 -0.08 -1.40 -6.08 -6.20 -3.25
Non-Cash Adjustments To Reconcile Net Income		 0.49 4.71 11 13 13 15
Changes in Operating Assets and Liabilities, net		 -0.81 1.40 2.00 0.73 -0.99 3.11
Net Cash From Investing Activities		 -34 -54 -221 53 44 23
Net Cash From Continuing Investing Activities		 -34 -54 -221 53 44 23
Purchase of Property, Plant & Equipment		 -0.08 -1.54 -0.92 -0.26 -0.34 -0.19
Purchase of Investments		 -56 -86 -313 -225 -230 -292
Sale of Property, Plant & Equipment		 - 0.00 0.04 0.00 0.00 0.00
Sale and/or Maturity of Investments		 22 34 93 277 274 315
Net Cash From Financing Activities		 45 379 0.24 0.72 0.51 26
Net Cash From Continuing Financing Activities		 45 379 0.24 0.72 0.51 26
Repayment of Debt		 -0.40 0.00 -0.43 0.00 0.00 0.00
Issuance of Common Equity		 0.00 254 0.34 0.31 0.48 25
Other Financing Activities, net		 0.00 0.03 0.32 0.42 0.04 0.24

Quarterly Cash Flow Statements for Design Therapeutics

This table details how cash moves in and out of Design Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 0.75 -6.74 8.20 16 -15 -7.77 -8.90 6.04 -4.62 1.77 -4.09
Net Cash From Operating Activities		 -15 -13 -12 -11 -9.55 -9.86 -17 -14 -11 -12 -16
Net Cash From Continuing Operating Activities		 -15 -13 -12 -11 -9.55 -9.86 -17 -14 -11 -12 -16
Net Income / (Loss) Continuing Operations		 -16 -12 -11 -12 -13 -14 -18 -19 -17 -16 -18
Consolidated Net Income / (Loss)		 -16 -12 -11 -12 -13 -14 -18 -19 -17 -16 -18
Depreciation Expense		 0.14 0.14 0.14 0.15 0.15 0.15 0.16 0.15 0.16 0.16 0.16
Amortization Expense		 -1.71 -1.84 -1.73 -1.57 -1.46 -1.44 -1.06 -0.91 -0.77 -0.51 -0.15
Non-Cash Adjustments To Reconcile Net Income		 3.23 2.73 3.19 3.30 3.12 3.47 3.54 4.41 3.58 3.43 3.99
Changes in Operating Assets and Liabilities, net		 -0.40 -1.99 -2.93 -1.35 1.68 1.61 -1.71 0.99 2.86 0.96 -2.80
Net Cash From Investing Activities		 15 5.56 21 27 -5.83 1.83 7.87 20 6.51 -12 -7.59
Net Cash From Continuing Investing Activities		 15 5.56 21 27 -5.83 1.83 7.87 20 6.51 -12 -7.59
Purchase of Property, Plant & Equipment		 -0.05 -0.03 -0.20 -0.16 0.02 - -0.07 -0.09 - -0.03 0.00
Purchase of Investments		 -55 -74 -46 -54 -67 -64 -87 -40 -78 -88 -53
Sale and/or Maturity of Investments		 70 80 66 81 61 66 94 60 85 76 45
Net Cash From Financing Activities		 0.01 0.50 0.02 0.23 0.00 0.26 0.02 0.36 0.04 25 20
Net Cash From Continuing Financing Activities		 0.01 0.50 0.02 0.23 0.00 0.26 0.02 0.36 0.04 25 20
Issuance of Common Equity		 - 0.10 - - - 0.25 0.00 - - 25 20
Other Financing Activities, net		 0.01 0.40 0.02 0.01 0.00 0.01 0.02 - 0.04 0.18 0.03

Annual Balance Sheets for Design Therapeutics

This table presents Design Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 37 391 341 290 252 226
Total Current Assets		 36 385 335 285 248 224
Cash & Equivalents		 2.38 299 27 21 23 17
Short-Term Investments		 34 85 304 261 223 203
Prepaid Expenses		 0.14 1.37 4.73 2.79 2.56 3.94
Plant, Property, & Equipment, net		 0.07 1.51 1.95 1.69 1.41 0.98
Total Noncurrent Assets		 0.21 3.61 4.07 3.37 2.64 1.44
Other Noncurrent Operating Assets		 0.21 3.61 4.07 3.37 2.64 1.44
Total Liabilities & Shareholders' Equity		 37 391 341 290 252 226
Total Liabilities		 2.48 8.43 14 12 10.00 14
Total Current Liabilities		 2.33 5.28 11 9.62 8.46 13
Accounts Payable		 2.33 5.28 11 9.62 8.46 13
Total Noncurrent Liabilities		 0.15 3.14 3.05 2.33 1.53 0.65
Other Noncurrent Operating Liabilities		 0.15 3.14 3.05 2.33 1.53 0.65
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -11 382 327 278 242 213
Total Preferred & Common Equity		 -11 382 327 278 242 213
Total Common Equity		 -11 382 327 278 242 213
Common Stock		 0.45 430 441 455 469 509
Retained Earnings		 -12 -47 -111 -178 -227 -297
Accumulated Other Comprehensive Income / (Loss)		 0.16 -0.24 -3.36 0.06 0.48 0.40

Quarterly Balance Sheets for Design Therapeutics

This table presents Design Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 300 279 270 262 237 223 212 230
Total Current Assets		 295 274 265 257 234 220 209 227
Cash & Equivalents		 28 29 46 30 14 20 15 13
Short-Term Investments		 263 241 215 224 216 197 191 210
Prepaid Expenses		 3.60 3.20 3.83 3.17 3.97 3.52 3.06 4.23
Plant, Property, & Equipment, net		 1.78 1.72 1.73 1.56 1.38 1.26 1.10 0.82
Total Noncurrent Assets		 3.55 3.19 3.01 2.83 2.45 1.83 1.64 2.57
Other Noncurrent Operating Assets		 3.55 3.19 3.01 2.83 2.45 1.83 1.64 2.57
Total Liabilities & Shareholders' Equity		 300 279 270 262 237 223 212 230
Total Liabilities		 15 9.24 8.34 9.18 9.56 9.85 12 12
Total Current Liabilities		 12 7.09 6.39 7.43 8.24 8.75 11 10
Accounts Payable		 12 7.09 6.39 7.43 8.24 8.75 11 10
Total Noncurrent Liabilities		 2.52 2.14 1.95 1.74 1.32 1.10 0.88 2.20
Other Noncurrent Operating Liabilities		 2.52 2.14 1.95 1.74 1.32 1.10 0.88 2.20
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 285 270 261 252 228 213 200 218
Total Preferred & Common Equity		 285 270 261 252 228 213 200 218
Total Common Equity		 285 270 261 252 228 213 200 218
Common Stock		 452 458 462 465 472 477 480 533
Retained Earnings		 -166 -189 -201 -214 -245 -264 -281 -315
Accumulated Other Comprehensive Income / (Loss)		 -1.28 -0.17 -0.22 0.91 0.45 0.31 0.36 -0.27

Annual Metrics And Ratios for Design Therapeutics

This table displays calculated financial ratios and metrics derived from Design Therapeutics' official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 55,662,501.00 55,910,071.00 56,001,992.00 - 56,963,757.00
DEI Adjusted Shares Outstanding		 0.00 55,662,501.00 55,910,071.00 56,001,992.00 - 56,963,757.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -0.64 -1.13 -1.19 - -1.23
Growth Metrics		 - - - - - -
Profitability Metrics		 - - - - - -
Net Operating Profit after Tax (NOPAT)		 -5.83 -25 -47 -55 -44 -56
Return On Investment Capital (ROIC_SIMPLE)		 - - - -19.71% -18.04% -26.18%
Earnings before Interest and Taxes (EBIT)		 -8.28 -36 -63 -78 -62 -79
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -8.35 -35 -64 -84 -68 -82
Valuation Ratios		 - - - - - -
Leverage & Solvency		 - - - - - -
Liquidity Ratios		 - - - - - -
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -25 -46 -54 -44 -52
Efficiency Ratios		 - - - - - -
Capital & Investment Metrics		 - - - - - -
Invested Capital		 -2.05 -1.93 -3.08 -4.11 -3.38 -7.34
Increase / (Decrease) in Invested Capital		 0.00 0.12 -1.14 -1.03 0.73 -3.96
Book Value per Share		 ($0.72) $6.87 $5.85 $4.96 $4.28 $3.73
Tangible Book Value per Share		 ($0.72) $6.87 $5.85 $4.96 $4.28 $3.73
Total Capital		 34 382 327 278 242 213
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -36 -384 -330 -282 -245 -220
Capital Expenditures (CapEx)		 0.08 1.54 0.88 0.26 0.34 0.19
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -2.19 -3.91 -6.04 -6.84 -5.90 -9.12
Debt-free Net Working Capital (DFNWC)		 34 380 324 275 240 211
Net Working Capital (NWC)		 34 380 324 275 240 211
Net Nonoperating Expense (NNE)		 2.45 10 16 12 5.92 14
Net Nonoperating Obligations (NNO)		 -36 -384 -330 -282 -245 -220
Total Depreciation and Amortization (D&A)		 -0.07 0.05 -0.99 -5.55 -5.60 -2.63
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($0.77) ($1.14) ($1.19) ($0.88) ($1.22)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 55.70M 55.71M 55.98M 56.59M 57.33M
Adjusted Diluted Earnings per Share		 $0.00 ($0.77) ($1.14) ($1.19) ($0.88) ($1.22)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 55.70M 55.71M 55.98M 56.59M 57.33M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($0.77) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 45.94M 55.94M 56.49M 56.76M 61.67M
Normalized Net Operating Profit after Tax (NOPAT)		 -5.83 -25 -47 -55 -44 -56
Debt Service Ratios		 - - - - - -
Payout Ratios		 - - - - - -

Quarterly Metrics And Ratios for Design Therapeutics

This table displays calculated financial ratios and metrics derived from Design Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 55,945,551.00 56,001,992.00 56,494,271.00 56,495,039.00 56,620,525.00 - 56,762,678.00 56,768,678.00 56,948,126.00 56,963,757.00 61,672,279.00
DEI Adjusted Shares Outstanding		 55,945,551.00 56,001,992.00 56,494,271.00 56,495,039.00 56,620,525.00 - 56,762,678.00 56,768,678.00 56,948,126.00 56,963,757.00 61,672,279.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.28 -0.21 -0.20 -0.21 -0.23 - -0.31 -0.34 -0.30 -0.28 -0.29
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBITDA Growth		 3.84% 7.15% 21.27% 22.34% -1.08% -6.92% -33.34% -35.63% -13.53% - 7.61%
EBIT Growth		 10.82% 12.80% 25.37% 24.55% -2.89% -10.40% -41.79% -43.38% -18.87% - 3.49%
NOPAT Growth		 1.93% 22.02% 33.49% 33.43% 13.69% -10.40% -41.79% -43.38% -18.87% - 3.49%
Net Income Growth		 10.82% 31.71% 42.44% 40.85% 17.42% -15.28% -59.52% -61.82% -30.36% - 0.45%
EPS Growth		 12.50% 35.48% 42.86% 41.67% 17.86% -20.00% -55.00% -61.90% -30.43% - 6.45%
Operating Cash Flow Growth		 -4.57% 15.19% 28.61% 18.43% 34.32% 22.96% -34.97% -28.25% -16.93% - 2.13%
Free Cash Flow Firm Growth		 7.39% 23.17% 14.58% 41.88% -43.65% -30.01% -18.58% -8.16% 43.51% - 21.12%
Invested Capital Growth		 -59.08% -33.60% 56.14% 0.00% 72.91% 17.78% -55.45% -1,533.19% -285.56% - -171.74%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBITDA Q/Q Growth		 18.11% 3.12% 4.94% -2.98% -6.58% -25.39% -18.55% -4.75% 10.78% - -6.32%
EBIT Q/Q Growth		 20.81% 4.23% 4.77% -4.47% -8.00% -28.03% -22.31% -5.64% 10.47% - -8.46%
NOPAT Q/Q Growth		 16.70% 19.66% 4.77% -4.47% -8.00% -2.76% -22.31% -5.64% 10.47% - -8.46%
Net Income Q/Q Growth		 20.81% 25.00% 6.22% -6.20% -10.57% -4.69% -29.77% -7.72% 10.93% - -10.25%
EPS Q/Q Growth		 22.22% 28.57% 0.00% -5.00% -9.52% -4.35% -29.17% -9.68% 11.76% - -7.41%
Operating Cash Flow Q/Q Growth		 -5.29% 11.94% 2.81% 9.48% 15.22% -3.29% -70.27% 13.99% 22.71% - -37.31%
Free Cash Flow Firm Q/Q Growth		 40.81% 12.81% -20.67% 6.67% -46.28% 21.08% -10.07% 14.88% 23.59% - -23.11%
Invested Capital Q/Q Growth		 0.00% 31.29% 72.54% 120.02% -817.26% -108.51% 48.08% -84.56% -92.96% - 35.04%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00%
Interest Burden Percent		 100.00% 78.31% 77.12% 78.40% 80.26% 81.77% 86.76% 88.47% 88.02% - 89.50%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Equity (ROE)		 -23.12% -22.10% -20.15% -19.34% -17.78% -19.08% -22.59% -26.77% -29.83% - -31.26%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% -39,465.66% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Common Equity (ROCE)		 -23.12% -22.10% -20.15% -19.34% -17.78% -19.08% -22.59% -26.77% -29.83% - -31.26%
Return on Equity Simple (ROE_SIMPLE)		 -25.39% 0.00% -21.77% 0.00% 0.00% 0.00% -24.66% 0.00% 0.00% - 0.00%
Net Operating Profit after Tax (NOPAT)		 -13 -11 -10 -11 -11 -12 -14 -15 -14 -13 -14
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Net Nonoperating Expense Percent (NNEP)		 -0.82% -0.41% -0.35% -0.97% -0.61% -0.75% -1.37% -1.67% -1.51% - -1.70%
Return On Investment Capital (ROIC_SIMPLE)		 - -3.81% -3.74% -4.03% -4.50% -4.83% -6.27% -7.09% -6.77% -5.99% -6.33%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings before Interest and Taxes (EBIT)		 -16 -15 -14 -15 -16 -17 -20 -22 -19 -18 -20
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -17 -17 -16 -16 -18 -18 -21 -22 -20 -19 -20
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.46 0.53 0.84 0.72 1.21 1.44 0.96 0.90 2.15 - 3.01
Price to Tangible Book Value (P/TBV)		 0.46 0.53 0.84 0.72 1.21 1.44 0.96 0.90 2.15 - 3.01
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Financial Leverage		 -1.02 -1.01 -1.01 -1.00 -1.01 -1.01 -1.01 -1.01 -1.02 - -1.01
Leverage Ratio		 1.05 1.04 1.04 1.03 1.04 1.04 1.04 1.04 1.05 - 1.05
Compound Leverage Factor		 1.05 0.82 0.80 0.81 0.84 0.85 0.90 0.92 0.92 - 0.94
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Altman Z-Score		 5.49 7.56 14.82 13.54 19.72 20.63 13.17 10.81 20.31 - 30.72
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 23.77 29.58 38.61 41.42 34.61 29.31 28.37 25.13 18.71 - 22.28
Quick Ratio		 23.48 29.29 38.16 40.82 34.19 29.01 27.89 24.73 18.43 - 21.87
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -11 -9.55 -12 -11 -16 -12 -14 -12 -8.89 -8.76 -11
Operating Cash Flow to CapEx		 -27,422.64% -47,400.00% -6,378.97% -6,993.79% 0.00% 0.00% -23,318.06% -16,598.85% 0.00% - 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -5.98 -4.11 -1.13 0.23 -1.62 -3.38 -1.76 -3.24 -6.25 -7.34 -4.77
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Increase / (Decrease) in Invested Capital		 -2.22 -1.03 1.45 0.23 4.36 0.73 -0.63 -3.47 -4.63 -3.96 -3.01
Enterprise Value (EV)		 -159 -133 -43 -72 51 104 -11 -25 223 - 433
Market Capitalization		 132 148 228 189 305 349 219 191 429 - 656
Book Value per Share		 $5.09 $4.96 $4.77 $4.62 $4.46 $4.28 $4.02 $3.75 $3.51 $3.73 $3.54
Tangible Book Value per Share		 $5.09 $4.96 $4.77 $4.62 $4.46 $4.28 $4.02 $3.75 $3.51 $3.73 $3.54
Total Capital		 285 278 270 261 252 242 228 213 200 213 218
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -291 -282 -271 -261 -254 -245 -230 -216 -206 -220 -223
Capital Expenditures (CapEx)		 0.05 0.03 0.20 0.16 -0.02 0.00 0.07 0.09 0.00 0.03 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -8.79 -6.84 -3.89 -2.57 -4.26 -5.90 -4.27 -5.23 -8.11 -9.12 -5.96
Debt-free Net Working Capital (DFNWC)		 282 275 267 258 250 240 225 211 198 211 217
Net Working Capital (NWC)		 282 275 267 258 250 240 225 211 198 211 217
Net Nonoperating Expense (NNE)		 2.61 1.26 1.03 1.26 1.67 1.97 3.42 3.98 3.48 3.28 3.84
Net Nonoperating Obligations (NNO)		 -291 -282 -271 -261 -254 -245 -230 -216 -206 -220 -223
Total Depreciation and Amortization (D&A)		 -1.57 -1.70 -1.59 -1.42 -1.30 -1.29 -0.90 -0.76 -0.61 -0.36 0.01
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.28) ($0.20) ($0.20) ($0.21) ($0.23) ($0.24) ($0.31) ($0.34) ($0.30) ($0.27) ($0.29)
Adjusted Weighted Average Basic Shares Outstanding		 55.99M 55.98M 56.49M 56.56M 56.62M 56.59M 56.76M 56.86M 56.95M 57.33M 61.43M
Adjusted Diluted Earnings per Share		 ($0.28) ($0.20) ($0.20) ($0.21) ($0.23) ($0.24) ($0.31) ($0.34) ($0.30) ($0.27) ($0.29)
Adjusted Weighted Average Diluted Shares Outstanding		 55.99M 55.98M 56.49M 56.56M 56.62M 56.59M 56.76M 56.86M 56.95M 57.33M 61.43M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 56.00M 56.49M 56.50M 56.62M 56.62M 56.76M 56.77M 56.95M 56.96M 61.67M 62.46M
Normalized Net Operating Profit after Tax (NOPAT)		 -13 -11 -10 -11 -11 -12 -14 -15 -14 -13 -14
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%

Financials Breakdown Chart

Key Financial Trends

The following is a concise, investor-friendly look at Design Therapeutics (DSGN) using the last four years of quarterly statements across cash flow, income statement, and balance sheet. Key takeaways are organized with positives first, then neutral, then negatives.

  • Equity financing inflows: The company has repeatedly raised capital via issuance of common stock, with roughly $25.1 million per quarter in several periods (e.g., Q1 2025, Q2 2025, and Q4 2025), helping fund operations through financing activities.
  • Substantial liquidity from short-term investments: Short-term investments run about $190–216 million through 2025, providing a sizable liquidity cushion for ongoing operations and strategic moves.
  • Significant cash inflows from sale/maturity of investments: In quarters like Q3 2025, sale/maturity of investments contributed about $84.6 million, and in Q4 2025 about $76.1 million, boosting cash receipts in those periods.
  • Positive net cash from continuing investing activities in some quarters: In Q2 2025, net cash from continuing investing activities was about $20.1 million, reflecting maturities/sales of investments that supported liquidity.
  • No product revenue in several periods: Total revenue is reported as $0 in multiple quarters (e.g., Q2–Q4 2025 and many prior periods), indicating the business has not yet generated product revenue.
  • Persistent net losses: Net income (loss) remains negative in every recent quarter (e.g., approximately -$16.0M in Q4 2025, -$17.0M in Q3 2025, -$19.1M in Q2 2025, -$17.7M in Q1 2025).
  • Operating cash burn continues: Cash flow from operating activities is negative across the period (e.g., about -$12.0M in Q4 2025 and Q3 2025, -$14.4M in Q2 2025, -$16.8M in Q1 2025), underscoring ongoing cash burn.
  • Rising accumulated deficit: Retained earnings are deeply negative and growing (e.g., -$281.0M in Q3 2025; -$264.0M in Q2 2025; -$244.9M in Q1 2025; -$188.7M in Q4 2024), signaling a substantial cumulative deficit.
  • Equity base trends lower despite some financings: Total equity declined from about $269.6M (Q4 2024) to roughly $199.7M (Q3 2025), suggesting dilution effects or continued losses despite occasional equity raises.
05/06/26 11:27 AM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Design Therapeutics' Financials

When does Design Therapeutics' financial year end?

According to the most recent income statement we have on file, Design Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

How has Design Therapeutics' net income changed over the last 5 years?

Design Therapeutics' net income appears to be on an upward trend, with a most recent value of -$69.79 million in 2025, rising from -$8.28 million in 2020. The previous period was -$49.59 million in 2024. See where experts think Design Therapeutics is headed by visiting Design Therapeutics' forecast page.

What is Design Therapeutics' operating income?
Design Therapeutics' total operating income in 2025 was -$79.47 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $79.47 million
How has Design Therapeutics' revenue changed over the last 5 years?

Over the last 5 years, Design Therapeutics' total revenue changed from $226 thousand in 2020 to $0.00 in 2025, a change of -100.0%.

How much debt does Design Therapeutics have?

Design Therapeutics' total liabilities were at $13.70 million at the end of 2025, a 37.1% increase from 2024, and a 453.5% increase since 2020.

How much cash does Design Therapeutics have?

In the past 5 years, Design Therapeutics' cash and equivalents has ranged from $2.38 million in 2020 to $298.57 million in 2021, and is currently $16.86 million as of their latest financial filing in 2025.

How has Design Therapeutics' book value per share changed over the last 5 years?

Over the last 5 years, Design Therapeutics' book value per share changed from -0.72 in 2020 to 3.73 in 2025, a change of -620.8%.


Related Companies

Financial statements for NASDAQ:DSGN last updated on 4/29/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
I’m sounding the alarm
Meta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...
Porter & Company | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel
Bigger than SpaceX, Tesla, xAI combined?!
The Wall Street legend who recommended Tesla in 2012 before its 16,724% move reveals... Musk's 2026 Project...
The Oxford Club | Sponsoredtc pixel
Get Ahead of Asia's Market Wave U.S. Solar Growth with PMAX.
Powell Max Limited (NASDAQ: PMAX) operates at the center of Hong Kong's $4.5 trillion capital markets, providi...
Smallcaps Daily | Sponsoredtc pixel
This AI stat will shock you …
AI stocks may be more overhyped than most investors realize - and one data point is making that case hard to i...
Weiss Ratings | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
"Computers are about to become obsolete" - George Gilder. Here’s why.
When the PC replaced the mainframe, companies that missed the shift went bankrupt. George Gilder - who called ...
Eagle Publishing | Sponsoredtc pixel